Chronic inflammation increases the risk of cancer and many cancers, including prostate cancer, arise at sites of chronic inflammation. Inducible nitric oxide synthase (iNOS) is an enzyme dominantly expressed during inflammatory reactions. Although synthesis of high amounts of nitric oxide (NO) by iNOS has been demonstrated in pathophysiological processes, such as acute or chronic inflammation, autoimmune diseases or tumorigenesis, the role of iNOS activity in most of these diseases is poorly understood. Analysing prostate cancer biopsies by immunohistochemistry we found iNOS protein expression in tumor cells strongly paralleled by nitrotyrosine suggesting that iNOS is fully active. In vitro, NO inhibits androgen receptor-dependent promoter activity and prostate specific antigen production as well as DNAbinding activity of the androgen receptor (AR) in a concentration-dependent manner. Inhibition of the activity of androgen receptor-dependent reporter constructs is neither owing to diminished AR protein levels nor owing to an inhibition of its nuclear import. In addition, NO inhibits the proliferation of androgen receptor-positive prostate cancer cells significantly more efficiently than proliferation of androgen receptor-negative prostate cancer cells. In summary, our findings suggest that intratumoral iNOS activity favors development of prostate cancer cells that are able to proliferate androgen receptor-independently, thereby promoting prostate tumor progression.
Chronic inflammation increases the risk of cancer and many cancers, including prostate cancer, arise at sites of chronic inflammation. Inducible nitric oxide synthase (iNOS) is an enzyme dominantly expressed during inflammatory reactions. Although synthesis of high amounts of nitric oxide (NO) by iNOS has been demonstrated in pathophysiological processes, such as acute or chronic inflammation, autoimmune diseases or tumorigenesis, the role of iNOS activity in most of these diseases is poorly understood. Analysing prostate cancer biopsies by immunohistochemistry we found iNOS protein expression in tumor cells strongly paralleled by nitrotyrosine suggesting that iNOS is fully active. In vitro, NO inhibits androgen receptor-dependent promoter activity and prostate specific antigen production as well as DNAbinding activity of the androgen receptor (AR) in a concentration-dependent manner. Inhibition of the activity of androgen receptor-dependent reporter constructs is neither owing to diminished AR protein levels nor owing to an inhibition of its nuclear import. In addition, NOIntroduction Inducible nitric oxide synthase (iNOS) is expressed in a variety of acute or chronic inflammatory human diseases as well as in various types of cancers including prostate cancer . Once expressed, iNOS produces high amounts of nitric oxide (NO) for prolonged periods of time which causes nitrosative stress. In the prostatic gland, expression of iNOS is already detectable in precancerous high-grade prostatic intraepithelial neoplasia (Wang et al., 2003) . In prostate cancer iNOS is expressed in 80-100% of prostate cancer specimens (Klotz et al., 1998; Aaltoma et al., 2001; Baltaci et al., 2001) , showing highest expression in locally advanced and metastasized tumors (Aaltoma et al., 2001) . Within the tumor, the majority of cells staining positive for iNOS are cancer cells (Klotz et al., 1998; Aaltoma et al., 2001; Baltaci et al., 2001; Wang et al., 2003; Bronte et al., 2005) . Moreover, a variable amount of inflammatory cells, presumably macrophages, inside and around the tumor equally express iNOS (Klotz et al., 1998; Aaltoma et al., 2001) . In contrast to prostate cancer, normal putatively undiseased prostatic tissue as well as tissue from benign prostatic hyperplasia stain negative or only weakly positive for iNOS (Klotz et al., 1998; Gradini et al., 1999; Aaltoma et al., 2001; Baltaci et al., 2001) . Although strong iNOS expression has been correlated to a rapid cancer cell proliferation rate, dedifferentiation and prediction of poor survival (Aaltoma et al., 2001) , the role of iNOS activity in prostate cancer remains unclear.
Prostate cancer is the second most common cause of tumor-associated death in men in the United States and accounts for 9% of all cancer-related deaths among men in the European Union. The prostate gland is the prototype of an androgen-responsive organ, because androgen plays a pivotal role in regulating growth and differentiation of normal as well as of malignant prostatic epithelial cells. As prostate tumor cells depend on androgens for growth and survival, androgen ablation by orchiectomy, anti-androgen treatment or treatment with luteinizing hormone releasing hormone analog are standard therapies for patients suffering from metastatic disease. These therapies result in an active process of programmed cell death in most prostatic cells. Unfortunately, after an initial response to androgen deprivation therapy, prostate cancer growth usually recurs in a form that is resistant to further antiandrogen treatment, and many men die of hormonerefractory, that is, androgen-independent prostate cancer (Feldman and Feldman, 2001; Cronauer et al., 2003) .
Androgens act via binding to the androgen receptor (AR), a ligand-dependent transcription factor of the nuclear steroid hormone receptor superfamily containing two cys 4 -type zinc-fingers. These zinc-fingers enable the AR to specifically recognize androgen-responsive elements (AREs), that is, palindromic DNA sequences in the promoters of androgen-responsive genes such as probasin or prostate-specific antigen (PSA). In the absence of androgens, the AR resides mainly in the cytoplasm in an inactive form associated with heatshock proteins. Upon androgen binding the AR dissociates from the heat-shock proteins, dimerizes and translocates into the nucleus where it binds to AREs thus inducing or enhancing androgen-dependent gene expression.
Initially it has been hypothesized that the AR is downregulated in cells of advanced, hormone-refractory tumors. However, recent studies demonstrate that most hormone-refractory prostate cancers are still expressing AR protein (Hobisch et al., 1996 (Hobisch et al., , 1998 , although it is not known to date whether these receptors are still fully functional. As zinc-finger transcription factors like the AR are redox-sensitive and therefore may be molecular targets during nitrosative stress caused by iNOS activity, we were interested in the effects of NO towards the AR. We found that iNOS colocalizes with nitrotyrosine staining in prostate cancer biopsies, suggesting a fully active iNOS in prostate cancer. In vitro, NO inhibits AR-mediated genomic function, which is not owing to diminished AR protein levels or to decreased nuclear AR translocation, but owing to inhibition of its DNA-binding activity. In addition, NO inhibits the proliferation of AR-positive human prostate cancer cells much more efficiently than proliferation of AR-negative, thus fully androgeninsensitive prostate cancer cells. Our findings suggest that nitrosative stress contributes to the generation of prostate cells that are able to proliferate AR independently. Thus, iNOS activity may play a putative fatal role in prostate cancer progression.
Results
Detection of iNOS and nitrotyrosine in prostate cancer biopsies Expression of iNOS protein has now been analysed in biopsies of more than 200 prostate cancer patients and was found to be expressed in prostate tumor cells in 80-100% of these patients (Klotz et al., 1998; Aaltoma et al., 2001; Baltaci et al., 2001; Wang et al., 2003; Bronte et al., 2005) . Despite these reports no data about iNOS activity in prostate cancer are available. To investigate this we first analysed tissue samples from five different prostate tumor patients by immunohistochemistry for the presence of iNOS. None of these patients was under anti-androgen treatment at the time the biopsy was taken. Expression of iNOS was found in all tumors analysed (Figure 1a ), but expression levels varied among the different tumors. Similar to published findings (Klotz et al., 1998; Aaltoma et al., 2001; Baltaci et al., 2001; Wang et al., 2003; Bronte et al., 2005) , iNOS staining was predominantly found in tumor cells and occasionally in basal cells and secretory epithelial cells of benign prostatic glands. In parallel we analysed the prostatic tumor samples for the presence of nitrotyrosine, a post-translational protein modification, as a measure for iNOS activity . Interestingly, iNOS expression intensities as well as iNOS expression patterns strongly paralleled nitrotyrosine staining (Figure 1b ). Immunohistochemical stainings for iNOS and nitrotyrosine were specific, as evidenced by negative control reactions, in which the respective primary antibodies were omitted (Figures 1c  and d) . Our results indicate that iNOS expressed in human prostate cancer is fully active and induces nitrosative stress.
NO inhibits androgen receptor-mediated genomic functions
In order to analyse whether treatment with a NO donor in vitro mimics iNOS activity in vivo, prostate cancer cells (22Rv1) were incubated with 400 mM of the longliving spontaneous NO donor (Z)-1-[N-(2-Aminoethyl)-N-(2-ammonioethyl)amino]diazen-1-ium-1,2-diolate (DETA/ NO) (half-life of about 8 h at 371C) (Berendji et al., 1997) for 30 h. Immunocytochemical analysis demonstrated the presence of intracellular nitrotyrosine (Figure 1f ), whereas neither untreated cells (Figure 1e ) nor cells treated with 400 mM of the control compound DETA (Figure 1g ) showed any staining. To analyse whether NO affects the genomic (transcriptional) response to androgen, AR-positive human prostate cancer cells (22Rv1) were transiently cotransfected with an androgen-responsive probasin-promoter driven reporter plasmid (pGL3E-Pro) and a pRL-tk-LUC Renilla vector as an internal control (Tepper et al., 2002; Cronauer et al., 2004) . Subsequently, cells were grown for 30 h in the presence of 10 nM of the synthetic androgen methyltrienolone (R1881) together with increasing concentrations of the DETA/NO for 30 h. DETA/NO inhibited transcriptional AR-activity in a concentration-dependent manner (Figure 2a ). Significant inhibition of reporter gene transactivation could already be detected at a DETA/NO concentration of 50 mM reaching 75% inhibition at 200 mM DETA/NO. Parallel incubation of the cells with 200 mM of the control compound DETA had no effect. In addition, DETA/NO inhibited R1881-induced PSA in LNCaP prostate cancer cells in a concentration-dependent manner reaching 54.7% inhibition with 400 mM DETA/ NO after 24 h (Figure 2b ). Furthermore, parallel transfection of 22Rv1 cells with pGL3E-Pro together with pCMV-iNOS-cds (containing the human iNOS coding region under the control of a cytomegalovirus (CMV) promoter) resulted in 83.2% inhibition of the AR-dependent reporter activity in the presence of R1881 compared to cells transfected with pGL3E-Pro plus pCMV empty vector (Figure 2c ).
NO does not affect AR protein expression or hormoneinduced nuclear translocation Inhibition of AR-dependent reporter gene activity by NO could be due to lower cellular AR protein expression levels as a consequence of either decreased AR synthesis or enhanced degradation of the AR, for example, by the proteasomal pathway, or owing to decreased nuclear AR translocation. Therefore the ARpositive LNCaP cells were cultured in the absence or Figure 1 Immunohistochemical analysis of iNOS expression and the presence of nitrotyrosine in primary prostate cancer or prostate cells treated in vitro with NO. In prostate cancer cells iNOS (a) and nitrotyrosine (b) were coexpressed as shown by staining of serial prostate cancer sections. As a negative control, additional serial sections were subjected to the same immunohistochemical staining protocol, except that the primary antibodies for iNOS (c) or nitrotyrosine (d) were omitted. Results are representative for five different prostate cancer patients. (a-d): original magnification Â 200. Nitrotyrosine-staining (green fluorescence) could also be found in prostate cancer cells (22Rv1) treated with 400 mM DETA/NO for 30 h (f), whereas untreated cells or cells treated with 400 mM of the control compound DETA were nitrotyrosine-negative (e, g). Cells were counterstained with DAPI (blue nuclear fluorescence).
presence of 10 nM R1881 with or without increasing concentrations of DETA/NO for 30 h and analysed for cellular AR concentrations by Western blotting. Treatment with R1881 yielded increased cellular AR levels compared to cells cultured in the absence of hormone ( Figure 3 ). However, neither up to 400 mM DETA/NO nor 400 mM DETA showed any effect on cellular AR protein levels. To investigate, whether NO affects nuclear AR translocation, DU-145 prostate cancer cells were transfected with a reporter construct coding for a fusion of the AR and the green fluorescent protein (GFP)-like AR-t1EosFP (Wiedenmann et al., 2004; Nienhaus et al., 2005) . In the absence of hormone, fluorescence activity was predominantly found in the cytoplasm (Figure 4a ), whereas 10 nM R1881 induced maximal nuclear translocation of the AR-t1EosFP construct after 6 h ( Figure 4b ). However, neither DETA/NO ( Figure 4c ) nor DETA ( Figure 4d ) at concentrations of up to 800 mM were able to decrease the percentage of R1881-treated cells with predominant nuclear fluorescence activity. In addition, experiments using AR-t1EosFP-transfected PC3 prostate cancer cells yielded identical results (not shown). In summary, these data show that NO neither decreases cellular AR protein levels nor hormone-induced nuclear AR import.
NO inhibits androgen receptor-binding to ARE NO has been shown to inhibit the DNA-binding activity of different members of the nuclear steroid hormone receptor superfamily, for example, the 1a,25-dihydroxyvitamin D3 receptor, the retinoid X receptor, and the estrogen receptor a (Kro¨ncke and Carlberg, 2000; Garba´n et al., 2005) . We therefore investigated by electrophoretic mobility shift assay (EMSA), whether NO affects the AR DNA-binding activity also. Prostate cancer cells (22Rv1) were incubated in the presence of 10 nM R1881 with increasing concentrations of DETA/ NO for 30 h. Subsequently, nuclear extracts were isolated and tested for AR-binding to ARE by EMSA. R1881 induced binding of the AR to its cognate ARE and increasing concentrations of DETA/NO decreased this DNA-binding activity with 400 mM DETA/NO inducing >90% inhibition ( Figure 5a ). In contrast, incubation with 400 mM DETA had no effect. Preincubation with a 200-fold excess of unlabeled ARE oligonucleotides or with specific anti-AR antibodies both resulted in inhibition of AR-DNA complex formation showing that the binding was AR-specific ( Figure 5b ). (22Rv1) were transfected with an androgen-responsive probasin-promoterdriven reporter plasmid (pGL3E-Pro) with or without pCMViNOS-cds and incubated with or without hormone for 30 h. Probasin promoter-driven luciferase activities were assessed and normalized by protein concentrations. Measurements were performed in quadruplicates. Shown is one representative out of two independent experiments. *Po0.04; **Po0.01; ***Po0.003; ****Po0.0002; þ Po0.02. To show whether NO may directly affect the DNAbinding activity of the AR, nuclear extracts of 22Rv1 cells treated with 10 nM R1881 for 30 h were isolated and incubated with increasing concentrations of the short-living spontaneous NO donor (Z)-1-(N,N-diethylamino)diazen-1-ium-1,2-diolate (DEA/NO) (half-life at room temperature (RT): about 16 min) (Keefer et al., 1996) . DEA/NO inhibited the AR DNA-binding activity in a concentration-dependent manner (Figure 5c ). More than 90% inhibition was found using 500 mM DEA/NO, whereas 500 mM of the denitrosated control compound DEA/NO ÀNO showed almost no effect. Incubation with increasing concentrations of S-nitrosocysteine, another spontaneous NO donor, as well as experiments using nuclear extracts of LNCaP prostate cancer cells yielded similar results (data not shown). In summary, these results show that NO inhibits the AR DNA-binding activity in a concentration-dependent manner.
Prostate cells which do not express AR are less susceptible to NO Effects of NO on cell proliferation were tested with ARnegative DU-145 cells as well as with AR-positive LNCaP and 22Rv1 prostate cancer cells (Stone et al., 1978; Horoszewicz et al., 1983; Sramkoski et al., 1999) . In contrast to LNCaP, which depend on androgenic stimuli for growth, proliferation of 22Rv1 cells is only weakly stimulated by androgens, although they are able to proliferate in the absence of androgens (Sramkoski et al., 1999; Attardi et al., 2004) . All three cell lines were treated with increasing concentrations of DETA/NO or with DETA which were given twice, at the beginning of the experiment and in addition 24 h later. After 48 h the percentage of living cells was determined using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide (MTT) assay. AR-positive prostate cell lines LNCaP and 22Rv1, respectively, were significantly more susceptible towards NO than the AR-negative DU-145 cells (Figure 6 ). These results indicate that AR-negative prostate tumor cells, which are able to proliferate fully AR independently, are more resistant towards nitrosative stress than androgen-sensitive prostate tumor cells.
Discussion
Epidemiologic data have correlated prostatitis and sexually transmitted infections with increased prostate cancer risk and, conversely, intake of anti-inflammatory drugs and antioxidants with decreased prostate cancer risk (Nelson et al., 2004) . Thus, chronic or recurrent inflammatory reactions within the prostate may initiate and promote prostate cancer development or progression. The iNOS is a prominent enzyme induced at inflammatory sites by proinflammatory cytokines and/ or bacterial products and has repeatedly been found to be expressed in prostate cancer (Klotz et al., 1998; Aaltoma et al., 2001; Baltaci et al., 2001; Wang et al., 2003; Bronte et al., 2005) , which is compatible with significantly elevated levels of the proinflammatory cytokines interleukin (IL)-6 and tumor necrosis factor (TNF)-a measured in serum of prostate cancer patients (Michalaki et al., 2004) . We here show that iNOS is fully active in prostate cancer, as staining for iNOS correlates with staining for nitrotyrosine (Figure 1 ), a post-translational protein modification reflecting enhanced NO production. This finding is supported by a recent study finding tyrosine nitration in prostate cancer specimens cultured for 4 days in vitro (Bronte et al., 2005) . In addition we show that treating prostate cancer cells with a NO donor also leads to intracellular nitrotyrosine formation thus connecting the in vivo data with our in vitro experiments. Effects of NO in tumor biology appear to be complex and are considered to have either stimulative or suppressive effects on tumor growth. At low concentrations, as synthesized by constitutively expressed NO synthases (eNOS, nNOS), NO appears to act as a signal molecule promoting tumor angiogenesis and tumor growth stimulation, whereas at higher concentrations, which typically are synthesized by iNOS, NO induces cytostatic or even cytotoxic effects towards cancer cells resulting in tumor growth inhibition or even in tumor regression. However, at higher concentrations, NO deactivates tumor-infiltrating cytotoxic T-lymphocytes or even induces lymphocytic apoptosis, thus participating in tumor-induced immunosuppression which may result in further tumor growth (for reviews see Thomsen and Miles (1998) ; Ekmekcioglu et al. (2005)).
Transfection of human prostate cancer cells with iNOS and subsequent implantation into the subcutis of nude mice suppressed growth of these cells compared to cells transfected with a control vector (Le et al., 2005) . In addition, interferon (IFN)-beta gene therapy was found to inhibit prostatic growth in wild-type but not in iNOS-null mice (Olson et al., 2006) . These results show that iNOS activity is able to produce anti-tumor activity. Moreover, treatment of prostate cancer cells with a NO donor inhibited constitutive DNA-binding of the zinc-finger transcriptional repressor Yin Yang 1 resulting in upregulation of Fas expression and tumor cell sensitivity to Fas-induced apoptosis (Garba´n and Bonavida, 2001; Hongo et al., 2005) . To elucidate the role of NO in prostate cancer progression we investigated effects of NO on the activity of the AR in prostate cancer cells. We found that NO dose dependently inhibited transactivation of the AR (Figure 2 ) as well as its DNA-binding activity ( Figure 5 ). The inhibitory effect of NO on AR activity is most likely owing to S-nitrosation of cysteine residues of the two cys 4 -type zinc-fingers which are essential for AR DNA-binding. Reaction of NO with cysteines of a zinc-finger has recently been demonstrated with another member of the nuclear steroid hormone receptor superfamily, the estrogen receptor a (Garba´n et al., 2005) . S-nitrosation of cysteines in zinc-finger domains leads to ejection of Zn 2 þ as has been demonstrated with the zinc-sulfur cluster containing proteins metallothionein and DnaJ, respectively, (Kro¨ncke et al., 1994 (Kro¨ncke et al., , 2001 Pearce et al., 2000) .
Nitrosative stress may inhibit cellular protein synthesis. In addition, S-nitrosothiols in proteins may further react with neighboring thiols, especially in zinc-sulfur clusters, yielding disulfides (Kro¨ncke et al., 1994) . As a result, these proteins may become partially unfolded thus exhibiting hydrophobic surface patches and therefore may be selectively recognized and degraded by the proteasome (Grune et al., 2003) . Indeed, treatment of the iron storage protein ferritin with NO increased its proteolytic susceptibility towards isolated 20S proteasome about 2.5-fold (Rudeck et al., 2000) . However, nitrosative stress did not result in diminished AR protein expression levels (Figure 3 ) nor in decreased hormone-induced nuclear AR translocation (Figure 4 ). These data indicate that NO-mediated inhibition of cellular AR activity is a direct effect disrupting AR DNA-binding activity.
Cancer growth depends on the ratio of proliferating cells to those dying. As androgen is the main regulator of this ratio in the prostate, both stimulating proliferation as well as inhibiting apoptosis, to date androgen ablation is the standard therapy to treat advanced prostate cancers. Although this treatment produces dramatical clinical responses, androgen ablation is mainly palliative as androgen-independent or hormonerefractory cancer cells develop during treatment. We found that NO inhibits proliferation of AR-positive prostate cancer cells significantly more efficiently than proliferation of AR-negative prostate cancer cells (Figure 6 ). Similar results have recently been found culturing prostate carcinoma cells in the presence of NO-donating non-steroidal anti-inflammatory drugs like nitrosulindac, NO-ibuprofen or NO-aspirin, which, after enzymatic cleavage release NO intracellularly. Using these compounds the AR-positive cell line LNCaP was found to be considerably more sensitive than AR-negative prostate cell lines like PC3 (Huguenin et al., 2004) , although this phenomenon appeared to be time-dependent (Royle et al., 2004) . Neoplastic tissue may be considered as a Darwinian microenvironment, where inflammatory products and/or growth factors select for tumor cells, which are able to proliferate signal independently. Experiments using a human prostate xenograft propagated in severe-combined immunodeficient mice showed that after prolonged periods of androgen deprivation, some of the cells resumed growth as androgen-independent cancers (Craft et al., 1999) . This is consistent with the hypothesis that hormone-refractory prostate cancer evolves through outgrowth of a small number of hormone-refractory cancer cells that develop at a low frequency during androgen ablation. The heparin-binding epidermal growth factor, which stimulates prostate tumor growth, has been identified as a factor that downregulates AR protein levels and promotes an androgen-independent phenotype of prostate cancer cells (Adam et al., 2002) pointing to the complex role of the AR in tumor growth regulation. We speculate that NO derived from iNOS may be another factor which provides selection pressure for clonal expansion of prostate tumor cells that are able to grow AR-independently. In addition, it is conceivable that NO-mediated inhibition of AR genomic functions may favor activation of rapid (non-genomic) androgendependent signaling pathways, a mechanism that recently has also been postulated for the estrogen receptor (Garba´n et al., 2005) .
Based on our in vitro observations, we conclude that long-term NO production by iNOS in prostate carcinoma may lead to a microenvironment favorable for androgen-independent prostate tumor progression thus explaining the correlation found between strong iNOS expression and poor survival of prostate cancer patients. In addition, our findings suggest that for prostate cancer chemoprevention suitable NO mimetics may have an additive effect to pharmacological androgen ablation.
Materials and methods

Materials
DETA/NO was synthesized as described (Hrabie et al., 2000) . DEA/NO was purchased from Sigma (Taufkirchen, Germany), oligonucleotides from Sigma-Genosys (Steinheim, Germany), the synthetic androgen methyltrienolone (R1881) from New England Nuclear (Dreieichenhain, Germany), restriction enzymes and the Sequenase DNA sequencing kit from Amersham-Pharmacia (Freiburg, Germany). The denitrosated control compound DEA/NO ÀNO was prepared by incubating 10 mM DEA/NO in phosphate-buffered saline (PBS) for 48 h at 371C. The probasin-promoter luciferasereporter plasmid (pGL3E-Probasin) was created by Dr R Matusik (Vanderbilt University, Nashville, TN, USA) and kindly provided by Dr Z Culig (Innsbruck Medical University, Innsbruck, Austria).
Immunohistochemistry and immunocytochemistry
Representative biopsy samples of five patients with prostate cancer varying in extent and malignant grade were used for immunohistochemistry. None of these patients was under antiandrogen treatment at the time the biopsy was taken. Primary antibodies for iNOS or nitrotyrosine were purchased from Abcam (Cambridge, UK). Staining protocols were performed according to the instructions from Abcam. Briefly, sections (5 mM) of formalin-fixed, paraffin-embedded tissue were deparaffinized and washed with Tris-buffered saline (TBS). Endogenous peroxidase activity was blocked by incubating with 1% H 2 O 2 for 5 min. Subsequently, antigen was retrieved by boiling for 10 min in 10 mM citrate buffer, pH 6.0 (iNOS) or in 1.0 mM ethylenediaminetetraacetic acid (EDTA) buffer, pH 8.0 (nitrotyrosine). After blocking for unspecific binding with TBS (pH 7.4) containing 5% bovine serum albumin (BSA)/ 0.2% Tween 20 for 60 min, sections were incubated for 1 h at RT in a moist chamber with rabbit polyclonal antibody to iNOS (ab15323; diluted 1:25 in blocking buffer) or with mouse monoclonal anti-nitrotyrosine antibody (ab7048; 1:50). Specimens were extensively washed (3 Â 10 min) with TBS/0.2% Tween 20 (pH 7.4), and the resulting immunocomplexes were detected by means of a commercial detection kit (LSAB System-HRP Kit, DAKO Diagnostika, Hamburg, Germany). Sections were counterstained with hematoxylin, dehydrated with ethanol, cleared with xylene and embedded in Eukitt (Kindler, Freiburg, Germany) .
For immunocytochemistry 22Rv1 cells were cultured on glass coverslips, washed (2 Â 5 min) with TBS, fixed with 3.5% paraformaldehyde (10 min at 41C), washed (2 Â 5 min) with TBS, and permeabilized for 10 min at RT with 0.5% Triton X-100 in TBS (TBT). After blocking for unspecific binding with TBT/5% BSA (TBTB; 1 h at RT), cells were incubated with mouse monoclonal anti-nitrotyrosine antibody (ab7048; 1:40 in TBTB for 1 h at RT), washed (4 Â 10 min) with TBT and incubated with mouse monoclonal anti-goat antibody labeled with Alexa Fluor 488 (Invitrogen, Karlsruhe, Germany; A11 001; 1:1 000 in TBTB for 1 h at RT). Cells were then washed (4 Â 10 min) with TBT and embedded in ProLong Gold antifade reagent containing 4 0 -6-diamidino-2-phenylindole (DAPI) (Invitrogen).
Cells
Human prostate cancer cell lines DU-145, LNCaP and 22Rv1 as well as human epithelial colon carcinoma DLD-1 cells were obtained from American Type Culture Collection (Manassas, VA, USA). DU-145 cells are AR-negative, whereas both LNCaP and 22Rv1 cells are AR-positive (Stone et al., 1978; Horoszewicz et al., 1983; Sramkoski et al., 1999) . Prostate cancer cells were routinely grown in Rosewell Park Memorial Institute (RPMI) 1640 medium, supplemented with 10% fetal bovine serum (FBS) and antibiotics. During experiments, cells were cultured in RPMI 1640 with 2.5% charcoal-treated steroid-free FBS (cFBS; Biochrom, Berlin, Germany) supplemented with 10 nM R1881. DLD-1 cells were routinely grown in Dulbecco's modified Eagle's medium/10% FBS, 2 mM L-glutamine, penicillin and streptomycin.
Generation of an eukaryotic iNOS expression plasmid DNA fragments containing the coding sequence (cds) of the human iNOS were generated by reverse transcriptionpolymerase chain reaction (RT-PCR) using the OneStep RT-PCR kit (Qiagen, Hilden, Germany), the oligonucleotides iNOS_cds_5P (5 0 -GGAGATCTCGAGATGGCCTGTCCTTG -3 0 ) and iNOS_cds_3P (5 0 -CCGCGGCCGCTCAGAGCGCT GACATCTCC-3 0 , sequences of the human iNOS cds underlined) and RNA isolated from cytokine-activated (100 U/ml IFN-g þ 50 U/ml IL-1b þ 10 ng/ml TNF-a) human DLD-1 cells as described (Kleinert et al., 1998) . The PCR products were digested with Bgl II and Not I, gel purified and inserted into the eucaroytic expression vector pEGFP-N1 (Invitrogen) digested with Bgl II and Not I and incubated with calf intestine alkaline phosphatase (Roche Diagnostics Corporation, Basel, Switzerland). The DNA sequence of integrated iNOS cds in the resulting plasmid pCMV-iNOS-cds was controlled using the dideoxy chain termination method.
Reporter gene assays Transient cotransfection assays were performed as described (Cronauer et al., 2004 (Cronauer et al., , 2005 . Briefly, cells were grown in 24-well plates and transfected with the probasin-promoter luciferase-reporter plasmid pGL3E-Probasin containing a 267-bp fragment of the rat probasin gene promoter (base positions À256 to þ 11). Together with pGL3E-Probasin a pRL-tk-LUC Renilla vector (Promega, Mannheim, Germany) was cotransfected to correct for transfection efficiency. Transfection was performed using FuGene6 (Roche Diagnostics Corporation) according to the manufacturer's instructions. After an incubation period of 12 h in RPMI 1640/5% cFBS, medium was changed to RPMI 1640/2.5% cFBS with or without 10 nM R1881 in the presence or absence of DETA/ NO. Reporter activity was analysed after a 30 h incubation period using the Dual-Luciferase Reporter Assay System (Promega). Firefly luciferase activities were then normalized by Renilla luciferase activities. Analysis of AR-signaling after iNOS overexpression was performed in AR-positive 22Rv1 prostate cancer cells. Therefore, 22Rv1 cells were transfected with the androgen-responsive reporter plasmid pGL3E-Pro with or without pCMV-iNOS-cds and incubated with or without hormone for 30 h. Probasin-reporter gene activities were assessed as described and normalized to protein concentrations. Protein concentrations were determined using the bincinchoninic acid Protein Assay (Pierce Biotechnology, Rockford, IL, USA).
Determination of PSA in supernatants of LNCaP cells LNCaP cells were seeded into 24-well plates and allowed to adhere for 24 h in RPMI-1640/10% FBS medium. After an additional incubation period of 12 h in RPMI-1640/10% cFBS 10 nM R1881 was added with increasing concentrations of DETA/NO. After 24 h PSA was assessed in the supernatants by enzyme immunosorbent assay (Roche Cobas Core PSA Total EIA, Roche Diagnostics Coorperation). PSA levels were normalized according to cell numbers using a Neubauer chamber.
Western blotting
Cell protein extracts from LNCaP cells cultured in T25 culture flasks for 48 h were prepared as described (Marth et al., 1990) . Protein extracts (30 mg) were electrophoresed in a 10% sodium dodecylsulfate-polyacrylamide gel and electroblotted onto nitrocellulose membranes. Nonspecific binding was blocked by incubation with 5% non-fat dry milk in PBS. Subsequently, membranes were incubated with AR-specific rabbit antibody PG-21 (1:500; Upstate, Lake Placid, NY, USA) and with mouse monoclonal anti-beta actin antibody (1:50 000; ab6276; Abcam) (Cronauer et al., 2000 (Cronauer et al., , 2004 . Immunoreactive bands were detected with peroxidase-labeled mouse anti-rabbit or anti-mouse antibodies (1:5000) and visualized by enhanced chemiluminescence (Amersham Pharmacia).
Nuclear translocation DU-145 prostate cancer cells were seeded into 12-well tissue culture plates and allowed to adhere overnight. Subsequently cells were transfected with 1 mg/well of green fluorescent AR-t1EosFP reporter construct (Wiedenmann et al., 2004; Nienhaus et al., 2005) for 4 h in RPMI 1640 and allowed to grow for another 24 h in RPMI 1640/5% cFBS. Cells were then cultured in RPMI 1640/2.5% cFBS in the presence or absence of 10 nM R1881 and DETA/NO or DETA for 6 h. Subsequently, localization of AR-t1EosFP was determined in 50-100 fluorescent cells. Cytoplasmic localization was defined, when the AR-t1EosFP fluorescence was greater in the cytoplasm than in the nucleus, and likewise, nuclear localization, when AR-t1EosFP fluorescence in the nucleus was greater than in the cytoplasm. Even distribution indicates that AR-t1EosFP fluorescence was evenly distributed between the nucleus and the cytoplasm.
EMSA
Nuclear protein extracts were isolated using the Nuclear Extract Kit from Active Motif (Carlsbad, CA, USA) with minor modifications. Briefly, cells (1 Â 10 7 ) were washed twice with ice-cold PBS/phosphatase inhibitors and scraped from the dish. All subsequent steps were performed at 41C. Cells were isolated by centrifugation (100 g for 5 min) and lysed in a hypotonic buffer (20 mM N-2-hydroxyethylpiperazine-N 0 -2-ethanesulfonic acid (Hepes), pH 7.5, 5 mM NaF, 10 mM Na 2 MoO 4 , 0.1 mM EDTA) for 15 min. After addition of Nonidet P-40 (final: 0.5%) nuclei were isolated by centrifugation (14 000 g for 30 s) and resuspended in lysis buffer AM1 in the presence of the protease inhibitor cocktail and 1 mM dithiothreitol. After 30 min in rotating Eppendorf tubes, nuclear proteins were isolated by centrifugation (14 000 g for 10 min), the protein concentrations determined (Bradford, 1976) , and the samples stored at À801C. For EMSA biotin end-labeled DNA doublex (200 fmol) of sequence 5 0 -AGCT TAGAACACAGTGTTCTCTAGAG-3 0 and 3 0 -ATCTTGTG TCACAAGAGATCTCCTAG-5 0 (Gast et al., 1995) were incubated with 0.5 mg of nuclear protein extract in the presence of 10 mM Hepes, pH 7.6, 30 mM KCl, 5 mM MgCl 2 , 5% glycerol, 1 mM EDTA, and 0.5 mg poly(dI-dC) for 15 min at RT (Cleutjens et al., 1996) . Unlabeled target DNA (40 pmol) or 2 ml of anti-AR antibody were added where indicated. Assays were loaded onto 6% polyacrylamide gels and electrophoresed in 45 mM Tris borate/1 mM EDTA buffer (pH 8.3) at 100 V and transferred onto a positively charged nylon membrane (Hybond-N þ ; Amersham Pharmacia Biotech). Transferred oligonucleotides were cross-linked to the membrane with UV-light (120 mJ/cm 2 ) and were detected by streptavidin-linked horseradish peroxidase using the LightShift Chemiluminescent EMSA Kit (Pierce Biotechnology, Rockford, IL, USA). Membranes were exposed to X-ray films for about 15 min, the bands scanned and relative intensities analysed by using Advanced Image Data Analyzer software (Raytest Isotopenmegeraete, Straubenhardt, Germany).
Cell viability assays
Cell viability was determined by means of two different assays, a colorimetric MTT assay measuring the reduction of tetrazolium salts to formazan derivatives by functional mitochondria (Mossmann, 1983; Park et al., 1987) , and a luminescence-based assay allowing to determine the number of viable cells based on quantification of intracellular ATP (Cell Titer-Glo Luminescent Cell Viability Assay; Promega) (Cronauer et al., 2005) . In a selected experiment, results of both assays were compared with those of trypan blue exclusion or the neutral red assay and were found to be identical (data not shown).
Statistical analysis
Data are reported as means7s.d. Analysis was performed with Student's t-test (two-tailed for independent samples) with Po0.05 considered as significant.
